Healthcare Technology Featured Article

September 01, 2011

Atlantic HIFU Introduces Non-Invasive Diagnosis and Treatment Options for Men with Prostate Cancer


Atlantic HIFU, global provider affordable quality prostate healthcare options recently introduced new non-invasive technology that is expected to revolutionize the prostate cancer diagnosis and treatment around the globe.

In a press release, Atlantic HIFU announced that it has developed an innovative medical imaging technology, called 3T MRI-S for the diagnosis and treatment of prostate cancer. This painless and non-invasive technology will replace the traditional biopsy method for diagnosing prostate cancer, according to the company.

3T MRI-S has been designed for all men with rising PSA or prior biopsies that help urologists diagnose and treat prostate disease and cancer more effectively than other imaging methods such as x-ray, ultrasound, or CAT. The technology also helps in the early detection of prostate cancer.

MRI-S utilizes a powerful 3.0 magnetic field, radio waves and innovative computer programming to produce the most detailed images available to differentiate abnormal (diseased) tissue from normal healthy tissue.

The method is capable of identifying the difference between prostate cancer and other benign conditions such as prostatitis and BPH.

Before a biopsy, MRI-S imaging read by a highly qualified Atlantic HIFU radiologist and urologist will identify if a biopsy is even necessary.

Another benefit of this technology is: it eliminates the need for random or repeat biopsies. Under this system, specialized urologists perform a biopsy that targets the specific area of suspicion not the entire organ.

Atlantic HIFU also offers the latest in non-invasive treatment options including Ablatherm HIFU, which is a robotic, incision and radiation-free procedure that uses highly focused ultrasound waves to ablate cancerous tissue within the prostate, while preserving normal bowel, urinary and sexual functions.

Ablatherm HIFU is recognized as a standard primary treatment for prostate cancer throughout Europe. Ablatherm HIFU awaits FDA approved in the United States and currently undergoing clinical trials.

Want to learn more about the latest in communications and technology? Then be sure to attend ITEXPO West 2011, taking place Sept. 13-15, 2011, in Austin, Texas. ITEXPO offers an educational program to help corporate decision makers select the right IP-based voice, video, fax and unified communications solutions to improve their operations. It's also where service providers learn how to profitably roll out the services their subscribers are clamoring for – and where resellers can learn about new growth opportunities. To register, click here.


Madhubanti Rudra is a contributing editor for HealthTechZone. To read more of her articles, please visit her columnist page.

Edited by Rich Steeves
Get stories like this delivered straight to your inbox. [Free eNews Subscription]




SHARE THIS ARTICLE



FREE eNewsletter

Click here to receive your targeted Healthcare Technology Community eNewsletter.
[Subscribe Now]